Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01169610 · ClinicalTrials.gov registry record · Phase 3
Varenicline and Alcohol in Inpatient Addictions Program (IAP)
A Phase 3 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT01169610: Clinical Trial Phase 3 study, sponsored by Mayo Clinic.
NCT01169610 is a Phase 3 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01169610, a Phase 3 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
The overall hypothesis of this line of research is that varenicline will decrease alcohol consumption and tobacco use and will increase alcohol and tobacco abstinence rates. In order to explore this hypothesis, the investigators will conduct a two-phase study: 1) an open label pilot study investigating the effect of varenicline on reduction of and abstinence from alcohol and tobacco; and 2) an optional MR spectroscopy to investigate whether glutamate and other brain metabolites correlate to measures of alcohol craving severity and/or subsequent varenicline treatment response.
Interventions
- DRUG Varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01169610
The ClinicalTrials.gov registry entry for NCT01169610 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Varenicline is the first listed.
NCT01169610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01169610 about?
NCT01169610 is a clinical study titled "Varenicline and Alcohol in Inpatient Addictions Program (IAP)". The overall hypothesis of this line of research is that varenicline will decrease alcohol consumption and tobacco use and will increase alcohol and tobacco abstinence rates. In order to explore this hypothesis, the investigators will conduct a two-phase study: 1) an open label pilot study investigat...
What is the current status of trial NCT01169610?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2011-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01169610?
The interventions under investigation include: Varenicline (DRUG).
Who is sponsoring clinical trial NCT01169610?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.